Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum

Neuroreport
H YamatoM Matsunaga

Abstract

We investigated the effect of fluoxetine, a selective serotonin reuptake inhibitor (SSRI), on L-DOPA-derived extracellular dopamine (DA) levels in the striatum of rats with nigrostriatal dopaminergic denervation using in vivo microdialysis. Treatment with fluoxetine (10 mg/kg, i.p.) induced a 41% reduction in the cumulative amount of extracellular DA during 300 min following L-DOPA administration (50 mg/kg, i.p.; p < 0.01). This effect was antagonized by pretreatment with WAY-100635, a potent 5-HT1A antagonist, indicating that this effect of fluoxetine is due to its indirect 5-HT1A agonistic property. These results suggest that SSRIs may impair motor functions in patients with Parkinson's disease by reducing efflux of exogenous L-DOPA-derived DA.

References

Feb 1, 1990·Archives of General Psychiatry·R J Baldessarini, E Marsh
Jan 1, 1990·Annals of the New York Academy of Sciences·D N Middlemiss, P H Hutson
Sep 9, 1986·European Journal of Pharmacology·J S Sprouse, G K Aghajanian
Jul 1, 1993·Trends in Pharmacological Sciences·F Artigas
Feb 1, 1996·Archives of Neurology·E TandbergJ L Cummings
Nov 11, 1998·European Journal of Pharmacology·I Hervás, F Artigas

❮ Previous
Next ❯

Citations

Sep 6, 2003·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Bruce R LawfordTerry L Ritchie
Jul 28, 2009·Neuroreport·Karen L Eskow JaunarajsChristopher Bishop
Oct 19, 2011·Parkinson's Disease·Sylvia Navailles, Philippe De Deurwaerdère
Jan 23, 2016·Pharmacology, Biochemistry, and Behavior·Melissa M ContiChristopher Bishop
May 9, 2012·Revue neurologique·P De Deurwaerdère, S Navailles
Jan 26, 2010·Neurobiology of Disease·Sylvia NavaillesPhilippe De Deurwaerdère
May 15, 2007·Acta Psychiatrica Scandinavica·M Brandt-ChristensenL V Kessing
Jul 5, 2006·The European Journal of Neuroscience·Christopher BishopPaul D Walker
May 17, 2008·CNS Neuroscience & Therapeutics·Jop P MostertJacques De Keyser
Jul 6, 2012·The European Journal of Neuroscience·Christopher BishopKaren L Eskow Jaunarajs
Apr 30, 2014·CNS Neuroscience & Therapeutics·Sylvia NavaillesPhilippe De Deurwaerdère
Mar 26, 2016·Progress in Neurobiology·Philippe De Deurwaerdère, Giuseppe Di Giovanni
Dec 8, 2004·Behavioural Brain Research·Daphna ShohamyMark A Gluck
Sep 10, 2005·Neuropsychologia·Daphna ShohamyMark A Gluck
Mar 27, 2015·Parkinson's Disease·Philippe HuotJonathan M Brotchie
May 29, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Cristina MiguelezPhilippe De Deurwaerdère
Jul 9, 2016·Progress in Neurobiology·Philippe De DeurwaerdèreMark J Millan
Sep 6, 2008·Progress in Brain Research·Susan H FoxJonathan M Brotchie
Jan 16, 2013·Pharmacological Reviews·Philippe HuotJonathan M Brotchie
Sep 29, 2017·Frontiers in Cellular Neuroscience·Cristina MiguelezPhilippe De Deurwaerdère
Dec 27, 2016·Frontiers in Neuroscience·Haruo Nishijima, Masahiko Tomiyama

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.